Skip to content

Study · Randomized controlled trial · n = 55 · 2026

9 results

Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).

Ajmera V, Vuppalanchi R, Khalili M, Sheikh MY, Risser J, Klein S, Tincopa M, Madamba E, Singh S, Siddiqi H, Cortez-Moreno D, Contrano D and 9 more

Show all authors

Hofflich H, Abeles R, Lunde O, Grunvald E, Bettencourt R, He F, Jain S, Richards L, Loomba R

Alimentary pharmacology & therapeutics12 Jan 2026Cited by 8 (Europe PMC)

PMID41527269 (opens in a new tab)DOI10.1111/apt.70516 (opens in a new tab)PepBankPUB-41527269
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with suspected at-risk MASH, semaglutide reduced the FAST score more than placebo over 52 weeks.

    In plain wordsIn adults with suspected liver disease from fat (MASH), semaglutide lowered the FAST liver score more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseFAST score change at end of treatment
    Study

    n = 55

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    2.4 mg weekly · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    FAST change
    −0.28 score
    semaglutide
    FAST change
    −0.12 score
    placebo

    Source sentences

    Summary
    The semaglutide group had a significantly greater reduction in FAST compared with placebo (-0.28 vs. -0.12; p = 0.002).
    1 context sentence
    Summary · context
    In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m2, or BMI ≥ 25 kg/m2 and prediabetes or type 2 diabetes with liver stiffness by VCTE ≥ 8 kPa and a FAST score ≥ 0.5 were randomised to eit…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with suspected at-risk MASH, more semaglutide recipients than placebo recipients achieved at least 5% weight loss (64% vs 8.3%).

    In plain wordsIn adults with suspected liver disease from fat, more people on semaglutide than on placebo lost at least 5% of body weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion with at least 5% weight loss
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg weekly · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    Weight loss >=5% responders
    64%
    semaglutide
    Weight loss >=5% responders
    8.3%
    placebo

    Source sentences

    Summary
    More semaglutide recipients achieved ≥ 5% weight loss (64% vs. 8.3%; p < 0.001) and ≥ 30% reduction in MRI-PDFF (60% vs. 17%; p = 0.047).
    1 context sentence
    Summary · context
    In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m2, or BMI ≥ 25 kg/m2 and prediabetes or type 2 diabetes with liver stiffness by VCTE ≥ 8 kPa and a FAST score ≥ 0.5 were randomised to eit…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with suspected at-risk MASH, more semaglutide recipients than placebo recipients achieved a reduction in MRI-PDFF of at least 30% (60% vs 17%).

    In plain wordsIn adults with suspected liver disease from fat, more people on semaglutide than on placebo cut liver fat by at least 30% on MRI.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion with at least 30% reduction in MRI-PDFF
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    2.4 mg weekly · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    MRI-PDFF reduction >=30% responders
    60%
    semaglutide
    MRI-PDFF reduction >=30% responders
    17%
    placebo

    Source sentences

    Summary
    More semaglutide recipients achieved ≥ 5% weight loss (64% vs. 8.3%; p < 0.001) and ≥ 30% reduction in MRI-PDFF (60% vs. 17%; p = 0.047).
    1 context sentence
    Summary · context
    In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m2, or BMI ≥ 25 kg/m2 and prediabetes or type 2 diabetes with liver stiffness by VCTE ≥ 8 kPa and a FAST score ≥ 0.5 were randomised to eit…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with suspected at-risk MASH, semaglutide led to a significantly greater reduction in ALT than placebo.

    In plain wordsIn adults with suspected liver disease from fat, semaglutide lowered the liver enzyme ALT more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseALT reduction
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    2.4 mg weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide led to a significantly greater reduction in ALT, AST, GGT, HbA1c and LDL cholesterol (p < 0.05).
    1 context sentence
    Summary · context
    In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m2, or BMI ≥ 25 kg/m2 and prediabetes or type 2 diabetes with liver stiffness by VCTE ≥ 8 kPa and a FAST score ≥ 0.5 were randomised to eit…
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with suspected at-risk MASH, semaglutide led to a significantly greater reduction in AST than placebo.

    In plain wordsIn adults with suspected liver disease from fat, semaglutide lowered the liver enzyme AST more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseAST reduction
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    2.4 mg weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide led to a significantly greater reduction in ALT, AST, GGT, HbA1c and LDL cholesterol (p < 0.05).
    1 context sentence
    Summary · context
    In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m2, or BMI ≥ 25 kg/m2 and prediabetes or type 2 diabetes with liver stiffness by VCTE ≥ 8 kPa and a FAST score ≥ 0.5 were randomised to eit…
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with suspected at-risk MASH, semaglutide led to a significantly greater reduction in GGT than placebo.

    In plain wordsIn adults with suspected liver disease from fat, semaglutide lowered the liver enzyme GGT more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseGGT reduction
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    2.4 mg weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide led to a significantly greater reduction in ALT, AST, GGT, HbA1c and LDL cholesterol (p < 0.05).
    1 context sentence
    Summary · context
    In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m2, or BMI ≥ 25 kg/m2 and prediabetes or type 2 diabetes with liver stiffness by VCTE ≥ 8 kPa and a FAST score ≥ 0.5 were randomised to eit…
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with suspected at-risk MASH, semaglutide led to a significantly greater reduction in HbA1c than placebo.

    In plain wordsIn adults with suspected liver disease from fat, semaglutide lowered HbA1c more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.4 mg weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide led to a significantly greater reduction in ALT, AST, GGT, HbA1c and LDL cholesterol (p < 0.05).
    1 context sentence
    Summary · context
    In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m2, or BMI ≥ 25 kg/m2 and prediabetes or type 2 diabetes with liver stiffness by VCTE ≥ 8 kPa and a FAST score ≥ 0.5 were randomised to eit…
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with suspected at-risk MASH, semaglutide led to a significantly greater reduction in LDL cholesterol than placebo.

    In plain wordsIn adults with suspected liver disease from fat, semaglutide lowered LDL cholesterol more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL cholesterol reduction
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2.4 mg weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide led to a significantly greater reduction in ALT, AST, GGT, HbA1c and LDL cholesterol (p < 0.05).
    1 context sentence
    Summary · context
    In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m2, or BMI ≥ 25 kg/m2 and prediabetes or type 2 diabetes with liver stiffness by VCTE ≥ 8 kPa and a FAST score ≥ 0.5 were randomised to eit…
  9. 09HumanRandomized controlled trialSafety outcome

    In adults with suspected at-risk MASH, gastrointestinal-related adverse events were common but not significantly different between semaglutide and placebo.

    In plain wordsIn adults with suspected liver disease from fat, stomach and gut side effects were common but not significantly different between semaglutide and placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeGastrointestinal-related adverse events
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.4 mg weekly · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal-related adverse events were common but not significantly different between the two groups (p = 0.59).
    1 context sentence
    Summary · context
    In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m2, or BMI ≥ 25 kg/m2 and prediabetes or type 2 diabetes with liver stiffness by VCTE ≥ 8 kPa and a FAST score ≥ 0.5 were randomised to eit…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.